Literature DB >> 24213914

HIV-1 coreceptor switch during 2 years of structured treatment interruptions.

S Baroncelli1, C M Galluzzo, M Andreotti, M F Pirillo, V Fragola, L E Weimer, M Giuliano, S Vella, L Palmisano.   

Abstract

The purpose of this investigation was to determine the impact on human immunodeficiency virus (HIV) tropism of uncontrolled virus exposure during 2 years of intermittent highly active antiretroviral therapy (HAART). The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) randomized study compared the outcome of 2 years of structured treatment interruptions (STIs) versus standard continuous treatment in first-line HAART responder subjects. The STI schedule consisted of five STIs of 1, 1, 2, 2, and 3 months, respectively, separated by four periods of 3-month therapy. In the present study, coreceptor tropism was assessed in 12 patients of the STI arm at different time points over a period of 2 years. Tropism was determined on DNA and RNA by V3 loop region sequencing. The Geno2pheno algorithm (false-positive rate, FPR: 20%) was used for data interpretation. At baseline, 9/12 subjects (75.0%) had CCR5-tropic viruses in their HIV. Three had a CXCR4-tropic virus. Ten patients maintained the same coreceptor in DNA after 2 years, whereas in two patients, a shift occurred (one R5-X4, one X4-R5). In a patient with an R5 virus at baseline, a transient change to X4 tropism was seen in the rebounding virus during STI. Changes in tropism were not associated with the amplitude and duration of virus exposure during STIs, residual viremia at baseline, or the development of resistance mutations in the RT region. Our preliminary results suggest that viral replication, observed after short periods of treatment interruption, is not enough to drive the evolution of HIV tropism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213914     DOI: 10.1007/s10096-013-1911-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

Authors:  Silvia Baroncelli; Clementina Maria Galluzzo; Liliana Elena Weimer; Maria Franca Pirillo; Anna Volpe; Alessandra Mercuri; Albertina Cavalli; Vincenzo Fragola; Laura Monno; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Raffaella Bucciardini; Marco Floridia
Journal:  J Antimicrob Chemother       Date:  2012-02-23       Impact factor: 5.790

2.  R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy.

Authors:  Pierre Delobel; Karine Sandres-Sauné; Michelle Cazabat; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Acquir Immune Defic Syndr       Date:  2005-04-01       Impact factor: 3.731

3.  Pitfalls of HIV genotypic tropism testing after treatment interruption.

Authors:  Marc Wirden; Cathia Soulié; Slim Fourati; Marc Antoine Valantin; Anne Simon; Nadine Ktorza; Roland Tubiana; Manuela Bonmarchand; Luminita Schneider; Vincent Calvez; Christine Katlama; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2012-09-06       Impact factor: 5.790

4.  Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.

Authors:  O Equils; E Garratty; L S Wei; S Plaeger; M Tapia; J Deville; P Krogstad; M S Sim; K Nielsen; Y J Bryson
Journal:  J Infect Dis       Date:  2000-08-15       Impact factor: 5.226

5.  Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years.

Authors:  Cathia Soulie; Sidonie Lambert-Niclot; Marc Wirden; Anne Simon; Marc-Antoine Valantin; Slim Fourati; Roland Tubiana; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  AIDS       Date:  2011-02-20       Impact factor: 4.177

Review 6.  European guidelines on the clinical management of HIV-1 tropism testing.

Authors:  L P R Vandekerckhove; A M J Wensing; R Kaiser; F Brun-Vézinet; B Clotet; A De Luca; S Dressler; F Garcia; A M Geretti; T Klimkait; K Korn; B Masquelier; C F Perno; J M Schapiro; V Soriano; A Sönnerborg; A-M Vandamme; C Verhofstede; H Walter; M Zazzi; C A B Boucher
Journal:  Lancet Infect Dis       Date:  2011-03-21       Impact factor: 25.071

7.  Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.

Authors:  S Philpott; B Weiser; K Anastos; C M Kitchen; E Robison; W A Meyer; H S Sacks; U Mathur-Wagh; C Brunner; H Burger
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

8.  The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.

Authors:  Laura Waters; Sundhiya Mandalia; Paul Randell; Adrian Wildfire; Brian Gazzard; Graeme Moyle
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

9.  Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters.

Authors:  Carmen de Mendoza; Kurt Van Baelen; Eva Poveda; Evelien Rondelez; Natalia Zahonero; Lieven Stuyver; Carolina Garrido; Jorge Villacian; Vincent Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

10.  Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.

Authors:  Lucia Palmisano; Marina Giuliano; Raffaella Bucciardini; Vincenzo Fragola; Mauro Andreotti; Clementina Galluzzo; Maria F Pirillo; Liliana E Weimer; Romano Arcieri; Elena A P Germinario; Roberta Amici; Maria Grazia Mancini; Antonella d'Arminio Monforte; Francesco Castelli; Pietro Caramello; Stefano Vella
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

View more
  3 in total

Review 1.  Antiretroviral therapy interruptions: impact on HIV treatment and transmission.

Authors:  Gueorgui Dubrocq; Natella Rakhmanina
Journal:  HIV AIDS (Auckl)       Date:  2018-06-13

2.  HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection.

Authors:  Monica Basso; Daniela Zago; Renzo Scaggiante; Silvia Cavinato; Irene Pozzetto; Camilla Stagni; Beatrice Parisatto; Anna Maria Cattelan; Giuliana Battagin; Loredana Sarmati; Saverio Giuseppe Parisi
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

3.  Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction.

Authors:  Anh Q Le; Jeremy Taylor; Winnie Dong; Rosemary McCloskey; Conan Woods; Ryan Danroth; Kanna Hayashi; M-J Milloy; Art F Y Poon; Zabrina L Brumme
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.